- Otherwise unexplained dyspnea, tachypnea, or chest pain.
- Clinical, ECG, or echocardiographic evidence of acute cor pulmonale.
- Positive chest CT angiography scan with contrast.
- High-probability ventilation-perfusion lung scan or high-probability
perfusion lung scan with a normal chest radiograph.
- Positive venous ultrasound of the legs with a convincing clinical
history and suggestive lung scan.
- Diagnostic contrast pulmonary angiogram.
The term “venous thromboembolism” (VTE) encompasses both pulmonary embolism (PE) and deep venous thrombosis (DVT) and accounts for more than 250,000 hospitalizations per year in the United States.
Venous thromboembolism constitutes one of the most common causes of cardiovascular and cardiopulmonary illnesses in Western civilization. Pulmonary embolism causes or contributes to at least 50,000 deaths per year in the United States, a rate that has probably remained constant
for the past three decades. For those who survive PE, further disability includes the potential development of chronic pulmonary hypertension or chronic venous insufficiency. After a VTE event, patients and their physicians are concerned about the presence of an occult carcinoma, the risk of a recurrent PE after anticoagulation therapy has been discontinued, and whether the patients’ family members are at risk for VTE.
“Primary” PE occurs in the absence of surgery or trauma. Patients with this condition often have an underlying
hypercoagulable state, although a specific thrombophilic condition
may not be identified. A common scenario is a clinically silent
tendency toward thrombosis, which is precipitated by a stressor
such as prolonged immobilization, oral contraceptives, pregnancy,
or hormone replacement therapy. Recently, there has been an increased appreciation of the risks of VTE among patients with medical illnesses,
including cancer (which itself may be associated with a hypercoagulable
state), congestive heart failure, and chronic obstructive pulmonary disease.
The prevalence of “secondary” PE is high among patients undergoing certain types of surgery, especially orthopedic surgery
of the hip and knee, gynecologic cancer surgery, major trauma, and
craniotomy for brain tumor. Pulmonary embolism in these patients
may occur as late as a month after discharge from the hospital.
Principal thrombophilic risk factors for VTE are listed in Table 26–1. The two most common genetic mutations that predispose to VTE are the factor V Leiden and the prothrombin gene. Both are autosomal-dominant. Whether factor V Leiden predisposes to recurrent VTE after anticoagulation is discontinued remains controversial. The prothrombin gene mutation is associated with
an increased risk of recurrent VTE after discontinuation of anticoagulation,
especially in patients who have coinherited the factor V Leiden mutation.
Table 26–1. Thrombophilic Risk Factors for Venous Thromboembolism. |Favorite Table|Download (.pdf)
Table 26–1. Thrombophilic Risk Factors for Venous Thromboembolism.
Factor V Leiden
Prothrombin gene mutation
Anticardiolipin antibodies (including lupus anticoagulant) as a feature of the antiphospholipid antibody syndrome
Hyperhomocysteinemia (usually due to folate deficiency)
Log In to View More
If you don't have a subscription, please view our individual subscription options below to find out how you can gain access to this content.
Want remote access to your institution's subscription?
Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.
If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
AccessMedicine Full Site: One-Year Subscription
Connect to the full suite of AccessMedicine content and resources including more than 250 examination and procedural videos, patient safety modules, an extensive drug database, Q&A, Case Files, and more.
Pay Per View: Timed Access to all of AccessMedicine
24 Hour Subscription $34.95
48 Hour Subscription $54.95
Pop-up div Successfully Displayed
This div only appears when the trigger link is hovered over.
Otherwise it is hidden from view.